Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase III trial compares the effect of xylitol dental wipes to dental wipes without xylitol for the reduction of bloodstream infection in children with acute myeloid leukemia (AML). Xylitol is a naturally occurring sugar compound found in fruits and vegetables. Xylitol has been shown to limit the growth of bacteria in the mouth, and to reduce cavities, plaque on the teeth, and inflammation of the gums. Treatment for AML includes chemotherapy. Patients receiving chemotherapy for AML have a risk of developing bloodstream infections. Bloodstream infections can make patients very sick, can contribute to delays in treatment, and can even cause death. In AML patients, bacteria or fungus (yeast) can sometimes enter the bloodstream from the mouth. Using xylitol dental wipes may help to reduce bloodstream infections in children being treated for AML.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek od 1 roku do 25 lat w momencie włączenia do badania
- •Potwierdzona diagnoza ostrej białaczki szpikowej (AML)
- •Planowane co najmniej 2 cykle chemioterapii, każdy zawierający określone leki
- •Co najmniej jeden widoczny ząb
- •Zgoda na uniknięcie produktów zawierających xylitol (guma, pasta do zębów) podczas badania
- •Pisemna zgoda pacjenta i rodziców/opiekunów
✗ Disqualifies
- •Białaczka związana z zespołem Downa
- •Wcześniejsza radioterapia głowy, szyi lub jamy ustnej w ciągu ostatnich 6 miesięcy
- •Uczulenie na xylitol
- •Uczulenie na winogrona lub smak winogronowy
- •Aktualnie leczone zakażenie krwi z pochodzeniem z jamy ustnej
- •Niemożliwość stosowania chusteczek do czyszczenia zębów
Simplified criteria — AI translation
Trial details
- Minimum age
- 1 Year
- Maximum age
- 25 Years
- Last updated (source)
- July 16, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (28)
Arkansas Children's Hospital
Little Rock, United States
Valley Children's Hospital
Madera, United States
Kaiser Permanente-Oakland
Oakland, United States
Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center
Denver, United States
Alfred I duPont Hospital for Children
Wilmington, United States
Nemours Children's Clinic-Jacksonville
Jacksonville, United States
Nemours Children's Hospital
Orlando, United States
Nemours Children's Clinic - Pensacola
Pensacola, United States
Children's Healthcare of Atlanta - Arthur M Blank Hospital
Atlanta, United States
Lurie Children's Hospital-Chicago
Chicago, United States
University of Kentucky/Markey Cancer Center
Lexington, United States
Norton Children's Hospital
Louisville, United States
Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
Grand Rapids, United States
Bronson Methodist Hospital
Kalamazoo, United States
Albany Medical Center
Albany, United States
Montefiore Medical Center - Moses Campus
The Bronx, United States
Rainbow Babies and Childrens Hospital
Cleveland, United States
ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital
Toledo, United States
Geisinger Medical Center
Danville, United States
Children's Hospital of Philadelphia
Philadelphia, United States
Children's Hospital of Pittsburgh of UPMC
Pittsburgh, United States
East Tennessee Childrens Hospital
Knoxville, United States
The Children's Hospital at TriStar Centennial
Nashville, United States
Dell Children's Medical Center of Central Texas
Austin, United States
Medical City Dallas Hospital
Dallas, United States
UT Southwestern/Simmons Cancer Center-Dallas
Dallas, United States
University of Virginia Cancer Center
Charlottesville, United States
Providence Sacred Heart Medical Center and Children's Hospital
Spokane, United States
Trial contact
Site Public Contact
Michael W. Bishop
PRINCIPAL_INVESTIGATOR
Site Public Contact
Ruetima Titapiwatanakun
PRINCIPAL_INVESTIGATOR
Site Public Contact
Aarati V. Rao
PRINCIPAL_INVESTIGATOR
Site Public Contact
Florence Choo
PRINCIPAL_INVESTIGATOR
Site Public Contact
Sridhi Patel
PRINCIPAL_INVESTIGATOR
Site Public Contact
Jeffrey H. Schwartz
PRINCIPAL_INVESTIGATOR
Site Public Contact
Tamara P. Miller
PRINCIPAL_INVESTIGATOR
Site Public Contact
Sara Zarnegar-Lumley
PRINCIPAL_INVESTIGATOR
Site Public Contact
James T. Badgett
PRINCIPAL_INVESTIGATOR
Site Public Contact
Michael J. Ferguson
PRINCIPAL_INVESTIGATOR
Site Public Contact
Kathleen Y. Butler
PRINCIPAL_INVESTIGATOR
Site Public Contact
Lauren R. Weintraub
PRINCIPAL_INVESTIGATOR
Site Public Contact
Alice Lee
PRINCIPAL_INVESTIGATOR
Site Public Contact
Duncan S. Stearns
PRINCIPAL_INVESTIGATOR
Site Public Contact
Jamie L. Dargart
PRINCIPAL_INVESTIGATOR
Site Public Contact
Jagadeesh Ramdas
PRINCIPAL_INVESTIGATOR
Site Public Contact
Rebecca Citrin
PRINCIPAL_INVESTIGATOR
Site Public Contact
Jean M. Tersak
PRINCIPAL_INVESTIGATOR
Site Public Contact
Susan E. Spiller
PRINCIPAL_INVESTIGATOR
Site Public Contact
Clinton M. Carroll
PRINCIPAL_INVESTIGATOR
Site Public Contact
Shannon M. Cohn
PRINCIPAL_INVESTIGATOR
Site Public Contact
Maurizio L. Ghisoli
PRINCIPAL_INVESTIGATOR
Site Public Contact
Gabriella Nguyen
PRINCIPAL_INVESTIGATOR
Site Public Contact
Brian C. Belyea
PRINCIPAL_INVESTIGATOR
Site Public Contact
Judy L. Felgenhauer
PRINCIPAL_INVESTIGATOR
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/14/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.